CNTA Stock Overview
A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Centessa Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.75 |
| 52 Week High | US$12.45 |
| 52 Week Low | US$3.96 |
| Beta | 1.45 |
| 1 Month Change | -12.50% |
| 3 Month Change | -18.60% |
| 1 Year Change | 91.47% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -59.77% |
Recent News & Updates
Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point
Apr 24Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?
Mar 07
Recent updates
Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point
Apr 24Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?
Mar 07Centessa Pharmaceuticals snaps multi-day losing streak; up 10%
Oct 20Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status
Sep 14Centessa Pharmaceuticals GAAP EPS of -$0.69
Aug 10Checking In On Centessa Pharmaceuticals
Dec 23Centessa Pharmaceuticals stock pops 20%+ intraday to post-IPO high
Jun 14Shareholder Returns
| CNTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.5% | 0.7% | 1.2% |
| 1Y | 91.5% | 5.0% | 27.7% |
Return vs Industry: CNTA exceeded the US Biotechs industry which returned 5% over the past year.
Return vs Market: CNTA exceeded the US Market which returned 27.7% over the past year.
Price Volatility
| CNTA volatility | |
|---|---|
| CNTA Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CNTA's share price has been volatile over the past 3 months.
Volatility Over Time: CNTA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 76 | Saurabh Saha | www.centessa.com |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.
Centessa Pharmaceuticals plc Fundamentals Summary
| CNTA fundamental statistics | |
|---|---|
| Market cap | US$960.30m |
| Earnings (TTM) | -US$138.42m |
| Revenue (TTM) | US$6.85m |
142.6x
P/S Ratio-7.1x
P/E RatioIs CNTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNTA income statement (TTM) | |
|---|---|
| Revenue | US$6.85m |
| Cost of Revenue | US$0 |
| Gross Profit | US$6.85m |
| Other Expenses | US$145.27m |
| Earnings | -US$138.42m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.24 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,019.80% |
| Debt/Equity Ratio | 35.7% |
How did CNTA perform over the long term?
See historical performance and comparison